Comparative Pharmacology
Head-to-head clinical analysis: TAZIDIME IN PLASTIC CONTAINER versus VELOSEF 250.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TAZIDIME IN PLASTIC CONTAINER versus VELOSEF 250.
TAZIDIME IN PLASTIC CONTAINER vs VELOSEF '250'
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ceftazidime inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), primarily PBP-3, leading to cell lysis and death. It is a beta-lactam antibiotic with activity against Gram-negative bacteria including Pseudomonas aeruginosa.
Bactericidal antibiotic that inhibits cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically inhibiting transpeptidase activity, leading to cell lysis.
1-2 g intravenously every 8 hours for most infections; up to 2 g every 6 hours for severe infections, particularly in neutropenic patients or those with cystic fibrosis.
250 mg orally every 6 hours for adults with normal renal function.
None Documented
None Documented
Terminal elimination half-life 1.7-2.0 hours in adults with normal renal function; prolonged to 12-30 hours in end-stage renal disease.
1.2-1.5 hours in normal renal function; prolonged in renal impairment (up to 10-20 hours in ESRD)
Primarily renal (80-90% unchanged via glomerular filtration and tubular secretion); biliary/fecal excretion accounts for <1%.
Primarily renal (80-90% unchanged by glomerular filtration and tubular secretion); remainder biliary/fecal (<10%)
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic